MedTrace Logo

Eculizumab (Soliris) in Covid-19 Infected Patients

NCT04288713 · Status: AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2020-03-30

No results posted yet for this study

Summary

Covid-19 has spread rapidly throughout the world causing widespread panic, death, and injury. While this virus is the provocateur, it is often the patient's own disproportionate immune response which deals the most devastating (and often fatal) damage. A specific part of the immune system, known as the complement, has been shown to cause such damage in other types of coronaviruses. In the SOLID-C19 study, Soliris (Eculizumab) will be used to modulate the activity of the distal complement preventing the formation of the membrane attack complex. By modulating this portion of the immune response, mortality can be halted while the patient has time to recover from the virus with supportive medical care.

Conditions

  • Coronavirus

Interventions

DRUG

Eculizumab

A distal complement inhibitor.

Sponsors & Collaborators

  • Hudson Medical

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04288713 on ClinicalTrials.gov